Pacira BioSciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St · 05/10 13:50

Pacira BioSciences (NASDAQ:PCRX) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$168.9m (up 1.1% from 1Q 2024).
  • Net income: US$4.81m (down 46% from 1Q 2024).
  • Profit margin: 2.8% (down from 5.4% in 1Q 2024).
  • EPS: US$0.10 (down from US$0.19 in 1Q 2024).
We check all companies for important risks. See what we found for Pacira BioSciences in our free report.
earnings-and-revenue-growth
NasdaqGS:PCRX Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pacira BioSciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 40%.

Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 5.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Pacira BioSciences' balance sheet health.